Medicure Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
July 28, 2023
Share
Medicure Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was CAD 5.99 million compared to CAD 5.75 million a year ago. Net income was CAD 0.253 million compared to net loss of CAD 0.683 million a year ago. Basic earnings per share from continuing operations was CAD 0.02 compared to basic loss per share from continuing operations of CAD 0.06 a year ago. Diluted earnings per share from continuing operations was CAD 0.02 compared to diluted loss per share from continuing operations of CAD 0.06 a year ago.
For the six months, sales was CAD 11.62 million compared to CAD 11.46 million a year ago. Net income was CAD 0.542 million compared to net loss of CAD 0.201 million a year ago. Basic earnings per share from continuing operations was CAD 0.05 compared to basic loss per share from continuing operations of CAD 0.02 a year ago. Diluted earnings per share from continuing operations was CAD 0.05 compared to diluted loss per share from continuing operations of CAD 0.02 a year ago.
Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Companyâs United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
MEDICURE INC. 
